A Multicenter, Open-label, Single Arm Phase IV Clinical Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Children With Achondroplasia
Latest Information Update: 08 Sep 2023
Price :
$35 *
At a glance
- Drugs Somatropin (Primary)
- Indications Achondroplasia
- Focus Therapeutic Use
- Sponsors GeneScience Pharmaceuticals
- 21 Feb 2023 Status changed from not yet recruiting to recruiting.
- 09 May 2022 New trial record